Structure Therapeutics (NASDAQ:GPCR) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $65.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets lifted their target price on Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a research note on Friday, June 7th. JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They issued an overweight rating and a $65.00 target price on the stock. Finally, JMP Securities reduced their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a research report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $84.63.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $38.26 on Monday. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $75.02. The firm’s 50-day simple moving average is $38.09 and its 200 day simple moving average is $39.64. The stock has a market cap of $1.78 billion, a PE ratio of -49.69 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, analysts predict that Structure Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Sandia Investment Management LP bought a new position in Structure Therapeutics in the 2nd quarter worth approximately $39,000. Quarry LP bought a new position in shares of Structure Therapeutics in the second quarter worth $79,000. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $163,000. Finally, Sei Investments Co. purchased a new stake in Structure Therapeutics during the 2nd quarter worth about $212,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.